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Reactogenicity to major tuberculosis antigens
absent in BCG is linked to improved protection
against Mycobacterium tuberculosis
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Ana Belen Gomez1,2, Santiago Uranga1,2, Ralf Spallek3, Mahavir Singh3, Regine Audran4,
Franc¸ois Spertini4 & Carlos Martin1,2,5,*
MTBVAC is a live-attenuated Mycobacterium tuberculosis vaccine, currently under clinical
development, that contains the major antigens ESAT6 and CFP10. These antigens are absent
from the current tuberculosis vaccine, BCG. Here we compare the protection induced by BCG
and MTBVAC in several mouse strains that naturally express different MHC haplotypes
differentially recognizing ESAT6 and CFP10. MTBVAC induces improved protection in C3H
mice, the only of the three tested strains reactive to both ESAT6 and CFP10. Deletion of both
antigens in MTBVAC reduces its efficacy to BCG levels, supporting a link between greater
efficacy and CFP10- and ESAT6-specific reactogenicity. In addition, MTBVAC (but not BCG)
triggers a specific response in human vaccinees against ESAT6 and CFP10. Our results
warrant further exploration of this response as potential biomarker of protection in MTBVAC
clinical trials.
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T
uberculosis (TB) disease causes around 1.5 million deaths
per year and is one of the leading airborne infectious
diseases affecting developing countries. The growing threat
of antibiotic-resistant strains makes TB treatment difficult or even
impossible. Thus, development of new vaccines able to prevent
respiratory forms of TB will have a tremendous impact in
preventing transmission and control of the disease1,2.
The current TB vaccine, Bacille Calmette–Guerin (BCG), is a
live-attenuated strain of the bovine pathogen Mycobacterium
bovis described to be protective against severe forms of TB
(meningitis and milliary TB) in children, but with inconsistent
and variable protection against pulmonary TB, which is
responsible for spread of the most common form of the disease
in adolescents and adults3. Developed a century ago by repeated
subculture, the principal genetic basis for BCG attenuation is the
loss of RD1 region, that includes the genes codifying for the major
virulence factors ESAT6 and CFP10, and other ones involved in
ESAT6/CFP10 secretion4,5. In addition to being major virulence
determinants, ESAT6 and CFP10 are the most immunogenic
proteins of M. tuberculosis, and ESAT6 is included in the
construction of promising TB vaccine candidates6–8.
MTBVAC is a live vaccine candidate rationally attenuated from
the clinical isolate M. tuberculosis Mt103 (ref. 9), which belongs
to lineage 4 (Euro–African–American), one of the most
widespread lineages of M. tuberculosis that conserves most of
the T-cell epitopes described for TB10. MTBVAC attenuation is
conferred by two independent unmarked deletions in the phoP
and fadD26 virulence genes, in accordance with the Geneva
Consensus requirements for the construction of live-attenuated
mycobacterial vaccines11. PhoP is a transcription factor that
controls B2% of the coding capacity of M. tuberculosis genome,
including production of immunomodulatory cell-wall lipids and
secretion of ESAT6 so that phoP mutants produce ESAT6 but are
unable to export it12. Deletion of fadD26 leads to complete
abolishment of phtioceroldimycocerosates (PDIM) synthesis,
known to be virulence lipids constituent of the envelope13.
MTBVAC has been characterized in different animal models
showing a safe, immunogenic and protective profile9,14–16.
MTBVAC is so far the first and only live-attenuated M.
tuberculosis vaccine that has entered clinical development. In
2015, MTBVAC successfully completed the first-in-human phase
1 clinical trial for safety and immunogenicity in healthy adult
volunteers in Switzerland17, which has allowed it to reach clinical
evaluation in newborns (clinical trial identifier: NCT02729571)
and adolescents (NCT02933281) in TB-endemic countries.
MTBVAC is being developed as preventive strategy against all
forms of the disease in newborns and adults.
Even though MTBVAC has demonstrated improved protection
compared to BCG in adult and newborn animal models9,14,16, the
mechanisms underlying its protective efficacy have not been
characterized. Elucidating these mechanisms remain crucial for
the identification of vaccine-specific biomarkers, which would
accelerate the clinical development of MTBVAC and would help
anticipate results from other TB vaccine candidates in the
preclinical and clinical pipeline.
The main support for the hypothesis that MTBVAC
may confer improved efficacy relative to BCG in humans is that
the MTBVAC genome maintains the whole T-cell antigen
repertoire of the human pathogen M. tuberculosis. This repertoire
includes those antigens located in RD1 and consequently absent
in BCG5. Here we assess the protection mediated by MTBVAC
in three different mouse genetic backgrounds, selected for
their differential ability to recognize and present ESAT6- and
CFP10-derived epitopes, to evaluate the potential protective role
of the immunogenicity mediated by these two major antigens
present in MTBVAC. Our results suggest that MTBVAC
immunogenicity against these major antigens, absent in BCG,
contributes to vaccine-induced protection, and highlight the
importance of host genetics in protective efficacy.
Results
ESAT6/CFP10 reactogenicity depends on host genetic back-
ground. Unlike BCG, MTBVAC contains the RD1 region and as
expected, we found that it differentially expressed esat6 (esxA-
Rv3875) and cfp10 (esxB-Rv3874) (Fig. 1a). Accordingly, ESAT6
and CFP10 proteins were present in the intracellular fraction of
MTBVAC but not BCG (Fig. 1b). Analysis of the secreted protein
fraction of MTBVAC revealed that ESAT6 was not released by
MTBVAC, which is in agreement with our previous results9.
Conversely, we found CFP10 in the MTBVAC extracellular
fraction (Fig. 1b,c), which was unexpected as these two proteins
are described to be co-secreted18. We next sought to evaluate
ESAT6- and CFP10-specific reactogenicity in different mouse
genetic backgrounds following MTBVAC vaccination. To do that,
we subcutaneously immunized with MTBVAC C57BL/6, BALB/c
or C3H/HeNRj mouse strains, each expressing a different
haplotype of the major histocompatibility complex (MHC);
H-2b, H-2d and H-2k, respectively. After vaccination,
splenocytes were stimulated with either purified protein
derivative (PPD) or single antigens ESAT6, CFP10 or Ag85B,
with the objective to elucidate the possible influence of the MHC
haplotype in the specific response against these proteins. Our data
revealed substantial differences among the three different mouse
strains (Fig. 2). MTBVAC vaccination conferred immunogenicity
to ESAT6 and Ag85B in C57BL/6 (Fig. 2a); to none of the single
antigens tested in this work in the BALB/c background (Fig. 2b);
and to ESAT6 and CFP10, but not to Ag85B, in the C3H/HeNRj
mouse strain (Fig. 2c). PPD-positive IFNg response in the BALB/
c mice suggested recognition by the H-2d haplotype of other
undefined exported mycobacterial proteins different from the
single antigens studied here, but present in the PPD. We found
that BCG did not induce any response to ESAT6 or CFP10
stimulation irrespective of the MHC alleles. Our results are in
accordance with previous work showing the exclusive capacity
of the H-2k haplotype of the C3H mouse strain to recognize
CFP10-derived peptides, in comparison to H-2b or H-2d of
C57BL/6 and BALB/c strains, respectively19.
Flow cytometry analysis of CD4þ IFNgþ splenocytes
confirmed the IFNg secretion profile observed by ELISA
(Supplementary Fig. 1a–c). In addition, analysis of IFNg-positive
splenocytes indicated that around 70% of this population
corresponded to CD4þ cells, whereas o5% were CD8þ cell,
suggesting that CD4þ T cells are major contributors of IFNg
production on antigen stimulation ex vivo (Supplementary
Fig. 1d,e).
Since our data revealed lack of Ag85B-specific response in
BCG-vaccinated C57BL/6 mice (Fig. 2a), we compared fbpB gene
expression and Ag85B secretion between BCG and MTBVAC.
Even though fbpB gene was similarly expressed by both vaccines
(Fig. 1a), Ag85B protein was not detected in the secreted fraction
of BCG (Supplementary Fig. 2), which could explain our in vivo
observations. Absence of Ag85B in the secreted fraction of
BCG could be justified by a recently described Phe140Leu
polymorphism in the fbpB gene of all BCG substrains predicting
an unstable protein20.
CFP10 and ESAT6 reactogenicity contributes to protection.
Eight weeks following BCG or MTBVAC subcutaneous vaccina-
tion, mice from the three strains were intranasally infected with a
low-dose challenge ofM. tuberculosis H37Rv (infectivity 20 CFU).
Four weeks later, bacterial load in lungs (Fig. 2d–f) and spleen
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms16085
2 NATURE COMMUNICATIONS | 8:16085 | DOI: 10.1038/ncomms16085 | www.nature.com/naturecommunications
(Fig. 2g–i) revealed protection of both vaccines as assessed by
bacterial load reduction relative to unvaccinated controls.
Nevertheless, whereas both BCG and MTBVAC protected to a
similar extent in C57BL/6 (Fig. 2d,g) and BALB/c (Fig. 2e,h)
mice, we observed a more pronounced bacterial load reduction in
C3H mice vaccinated with MTBVAC, as compared to BCG
(Fig. 2f,i).
As an additional control, we studied the replication and
dissemination profile of MTBVAC and BCG in the draining
lymph nodes and spleen of C3H mice (Supplementary Fig. 3).
The pattern observed resulted comparable, with no profound
differences between both vaccines, similar to that published
previously in BALB/c mice9. Altogether, these results suggest
that differences in protection between BCG and MTBVAC in
C3H mice were not due to a different biological behaviour of
the two vaccines.
To evaluate the contribution to protection of MTBVAC-
induced immune responses against CFP10 and ESAT6,
we constructed an MTBVAC substrain with deleted cfp10 and
esat6 genes (MTBVACDE6C10) (Fig. 3a). To construct this
mutant, we used a BAC-rec strategy that permitted us to
substantially accelerate the generation of deletion mutants in
M. tuberculosis (Supplementary Fig. 4). We found that mice
vaccinated with MTBVACDE6C10 showed inability to elicit
specific responses to CFP10 and ESAT6 (Fig. 3b,c). Interestingly,
IFNg production in C3H mice following PPD stimulation was
lower in the MTBVACDE6C10-vaccinated group compared
to MTBVAC-vaccinated control, suggesting that ESAT6 and
CFP10 are likely the main immunodominant antigens in this
genetic background. Importantly, MTBVACDE6C10 triggered an
Ag85B-specific response equivalent to the parental strain
(Fig. 3b), indicating that genetic manipulation did not alter the
ability of MTBVAC knockout to elicit antigen-specific immunity.
Protective efficacy studies in C57BL/6 mice (Fig. 3d,g), reactive
to ESAT6 but not CFP10, showed that immunization with
MTBVACDE6C10 or parental MTBVAC-conferred similar
protection, suggesting that ESAT6-specific immune response is
not sufficient for optimal efficacy of MTBVAC. Remarkably,
MTBVACDE6C10 vaccination of C3H mice, the only genetic
background reactive to both antigens studied in the present
work, conferred lower protection than MTBVAC vaccination
and comparable to BCG (Fig. 3f,i).
Confirming the capacity of I-Ak, I-Ek molecules to present
CFP10-derived peptides to CD4þ cells, we observed in vitro
that CD4þ cells purified from C3H mice vaccinated with
MTBVAC, but not with MTBVACDE6C10, produced IFNg when
incubated with CFP10-pulsed syngeneic bone-marrow-derived
macrophages in an antigen concentration-dependent fashion
(Supplementary Fig. 5).
In addition, an MTBVAC knockout for Ag85B was constructed
to evaluate the role of this antigen in MTBVAC-conferred
protection. Results showed that in the absence of Ag85B-specific
response, MTBVAC efficacy remained unaffected in any of the
three genetic backgrounds tested (Fig. 4).
Increased cfp10 and esat6 gene expression in vivo. Even though
we observed that MTBVAC induced a strong response specific
for CFP10, ESAT6 and Ag85B, our results indicate that only
reactogenicity against RD1-containing antigens, but not Ag85B,
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Figure 1 | Expression and secretion of ESAT6 and CFP10 by MTBVAC. (a) Normalized expression (using sigA as housekeeping gene) of fbpB, esat6 and
cfp10 genes in log-phase broth-cultured BCG and MTBVAC. Data in the graph are represented as the relative quantity (RQ) using MTBVAC as comparator.
Results are the average from triplicate experiments. Data are mean±s.d. (b,c) Immunoblot analysis of GroEL2, Ag85A, ESAT6 and CFP10 in BCG, MTBVAC
and M. tuberculosis protein extracts. (b) Intracellular (left) and supernatant (right) fractions of BCG and MTBVAC were assessed. (c) Comparison between
M. tuberculosis and MTBVAC-secreted fractions. A BCG cell lysate sample was used as positive control for GroEL2 detection. Four independent protein
extractions of each strain were included in the analysis. Full blots are shown in Supplementary Fig. 7a–c.
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contributed to protection. We hypothesized that this difference
could be related to the expression level of each of these
antigens by M. tuberculosis on early lung infection. Indeed, it
has been described that M. tuberculosis downregulates fbpB
(Ag85B-codifying gene) expression in vivo, as a mechanism to
impair host recognition21. Thus, we compared in vivo expression
of fbpA and fbpB with esat6, cfp10, espA and espC genes.
EspA and EspC are essential factors for ESAT6 and CFP10
secretion22–24. Thus, we intranasally infected C3H (Fig. 5a) and
C57BL/6 (Fig. 5b) mice with H37Rv, and 4 weeks later we isolated
intrapulmonary bacteria and analysed gene expression by
RT–qPCR. Expression levels were compared under in vivo
conditions and in culture using standard 7H9 media. Our data
revealed a comparable expression level for all the genes studied
under in vitro culture. Conversely, when studied in vivo,
we detected in both mouse strains an enriched expression
of esat6 and cfp10 genes, as well as espA and espC, relative to
fbpA and fbpB.
Of note, higher in vivo expression of esat6 relative to fbpB
has been previously described6,25. Our results extend these
observations to other genes from the ESX-1 secretion system,
including cfp10 and those involved in the secretion of ESAT6.
MTBVAC induces a CFP10-specific response in human vaccinees.
As our data showed a link between CFP10-/ESAT6-induced
reactogenicity following MTBVAC immunization and improved
protection compared to BCG, we sought to evaluate the induction
of responses against these antigens in MTBVAC-vaccinated
humans. We used the ESAT6- and CFP10-specific ELISPOT
data from the MTBVAC Phase 1 trial performed in adults in
Switzerland, which had concluded that none of the MTBVAC
vaccinees exceeded the spot threshold for positive latent
M. tuberculosis infection at the end of active follow-up study17.
We thus compared results from each individual before
(day 0) and after (day 210) vaccination with MTBVAC or BCG
(5 105 CFU vaccination dose), finding a significant increase in
the CFP10-specific response in the MTBVAC vaccinees (Fig. 6a).
For ESAT6, though results showed a rising tendency in the
group of MTBVAC, the increment was not significant (Fig. 6c).
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Figure 2 | Improved protection of MTBVAC compared to BCG is dependent on the host genetics. (a,b,c) Antigen-specific IFNg production following
stimulation with PPD (5mgml 1), ESAT6 (2 mgml 1), CFP10 (2mgml 1) and Ag85B (2mgml 1) during 48 h of splenocytes from mock-, BCG- and
MTBVAC-vaccinated C57BL/6, BALB/c and C3H/HeNRj mice. (d–i) Lung (d,e,f) and spleen (g,h,i) bacterial load 4 weeks post low-dose H37Rv intranasal
challenge. C57BL/6 (d,g), BALB/c (e,h) and C3H/HeNRj (f,i) were vaccinated with BCG, MTBVAC or unvaccinated eight weeks before challenge.
(a,b,c) Data are representative from one of two independent experiments (n¼ 5 mice per group per experiment). (d–i) Data in the graphs represent a pool
of two independent experiments (n¼ 12 mice per group). All data are mean±s.e.m. (a,b,c) NS, non-significant; ***Po0.001 by unpaired t-student test.
(d–i) NS, non-significant; *Po0.05; **Po0.01; ***Po0.001 by one-way ANOVA and Bonferroni post-test.
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Confirming assay specificity, none of the BCG-vaccinated
participants showed any increment in CFP10- and ESAT6-
specific responses at the end of the study (Fig. 6b,d). Therefore,
MTBVAC induces a CFP10-specific immune response in
humans.
Discussion
The MHC is composed of several highly polymorphic loci resulting
in a wide interindividual variability of MHC haplotypes, which can
have great influence in host-specific responsiveness to vaccines, as
individual haplotype may determine antigen immunodominance
associated with protection26. To date, there are no defined
BCG-specific immunodominant antigens associated with efficacy
against TB. The identification of such correlates of protection for
new TB vaccines, as MTBVAC, would greatly accelerate clinical
development to efficacy trials.
A plausible explanation for the poor protection of BCG against
pulmonary TB is the loss of several genomic regions, including
RD1 (refs 5,8), which encodes ESAT6, CFP10 and part of their
secretory machinery contained in the ESX-1 secretion system.
Despite their low molecular weight, ESAT6 and CFP10 are the
top two antigens with the highest proportion of peptides
recognized by human MHC haplotypes20,27. Importantly, loss
of RD1 has also been reported as the main basis for attenuation of
BCG5. Our results indicated that, unlike other major antigens not
related with virulence, such as those belonging to the Ag85
complex, ESAT6, CFP10 and the machinery involved in their
secretion are highly over expressed on early infection, which is
probably the result of their role in virulence and infection
establishment. Indeed, in agreement with these observations, the
phagosomal escape of M. tuberculosis, which is mediated by
ESAT6, occurs as early as day 3 after in vitro macrophage
infection28. Thus, a vaccine inducing an effective response against
ESAT6 and CFP10, such as MTBVAC, may have the advantage to
target antigens highly expressed during early M. tuberculosis
infection. This would probably lead to a better recognition of
M. tuberculosis-infected cells, whose MHC molecules should
be coated with epitopes derived from dominant antigens.
Conversely, vaccination-induced immunogenicity against other
antigens, such as Ag85A or Ag85B, underexpressed and therefore
less represented in the antigen repertoire at early infection stages,
would be less efficient against initial infection as a consequence of
a poorer recognition of pathogen-infected cells. In line with this,
other authors have demonstrated downregulation of Ag85B
expression during early M. tuberculosis infection21.
Our efficacy data in mice seem to contrast with previous results
using a recombinant BCG vaccine overexpressing Ag85B
(rBCG30), which showed an improved protection relative to
BCG in an outbred guinea pig model29. However, the different
animal model used in that study (more sensitive to TB) and the
different readout utilized to measure vaccine efficacy (survival)
could account for such differences.
An important proportion of human MHC class II haplotypes
recognizes ESAT6- and CFP10-derived peptides30. This could be
explained by the important roles played by both proteins in
virulence, eliciting an evolutionary pressure leading to the
selection of MHC human haplotypes that recognize
highly conserved peptides derived from these antigens. Our
results suggest that the immunodominance of ESAT6 and
CFP10 in humans is not reflected in mice, as only one of the
three haplotypes tested simultaneously presents both antigens.
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This difference could be due to lack of co-evolution of the mouse
MHC loci with ESAT6- and CFP10-expressing mycobacteria.
Indeed, Mycobacterium microti, the mycobacterial species that
naturally infects rodents, lacks the RD1mic region that includes
both genes5. Conversely, those species of the M. tuberculosis
complex able to infect humans (M. canettii, M. africanum and
M. tuberculosis) have retained intact esat6 and cfp10 genes as well
as their secretory machinery31,32.
Our previously published results in MTBVAC-vaccinated
newborn C57BL/6 mice showed a slight but significant
improvement of MTBVAC-conferred protection relative to
BCG in lungs of infected pups with an aerosol challenge
dose of H37Rv similar to the one used in the present work16.
This previous work also demonstrated that, unlike the
comparable immunogenicity of MTBVAC and BCG observed
in adult mice, MTBVAC was much more immunogenic
(following PPD stimulation) than BCG when animals were
vaccinated at birth, which could account for such difference in
protection. In two other studies9,33, where we vaccinated C57BL/6
adult mice, we also found an improved protection in the
MTBVAC group, although in those works we used a much
higher initial H37Rv challenge dose (100 and 1,000 CFU)
than the one we used in the present work (20 CFU). In line
with this, previous data in a guinea pig model revealed that
MTBVAC only improved BCG protection in high-dose challenge
experiments14, suggesting the contribution of undefined
mechanism(s) of protection occurring at different experimental
conditions than the tested in this work.
Our data indicate that both H-2b (C57BL/6) and H-2k
(C3H) haplotypes recognized ESAT6-derived epitopes following
MTBVAC immunization. However, MTBVAC only improves
BCG-conferred protection in C3H mice, the only of the three
tested genetic backgrounds whose MHC haplotype presents
CFP10-derived peptides. This result could suggest a particular
contribution of CFP10-specific reactogenicity to MTBVAC
protection. Interestingly, we found that MTBVAC secretes CFP10
but not ESAT6. Provided secreted proteins are differentially
processed by the host immune system in comparison to
intracellular proteins34, we speculate that ESAT6 and CFP10
might induce different responses in MTBVAC vaccinees, which
might lead to differential protection. In this regard, it could be
relevant in the future to construct MTBVAC mutant strains for
ESAT6 and CFP10 separately, to study these potential mechanisms
in more detail.
It has been reported that both ESAT6 and CFP10 are
co-secreted by M. tuberculosis18. Therefore, further work is
needed to elucidate the molecular mechanisms behind the
CFP10-independent secretion of ESAT6 in MTBVAC. Two
previous publications reported that uncoupled ESAT6 and
CFP10 secretion can occur under some conditions35,36. In these
studies, authors found that CFP10 is secreted independently of
ESAT6 in the presence of an aberrant ESX-1 system. Thus, we
speculate that since PhoP is a regulator of different genes
encoding ESX-1 components12,37,38, MTBVAC may express a
dysfunctional ESX-1 system responsible of the observed
phenotype.
Our study underlines the role of host genetics in vaccine-
induced protection and how genetic background determines
antigen immunodominance, as shown with CFP10 in the C3H
mouse strain. In line with this finding, the importance of host
genotype for tuberculosis susceptibility and vaccine protection
in the mouse model has been recently reported39. Thus, our
results indicate that MTBVAC-vaccinated mice reactogenic for
CFP10 and ESAT6 are more protected against tuberculosis than
non-reactogenic strains. In humans, responders to these antigens
comprise around 60–80% of individuals30,40. We speculate that a
vaccine expressing ESAT6 and CFP10 might confer improved
protection in these individuals (in comparison with BCG);
however, further clinical data would be needed to test this
hypothesis.
One of the handicaps of a vaccine whose protective mechanism
is based on ESAT6- and/or CFP10 antigens remains in
their potential interference with the latent TB diagnostic test.
Data provided by the first-in-human clinical trial of MTBVAC in
adults indicated that the ELISPOT response elicited by MTBVAC
following ESAT6 or CFP10 stimulation was below the cutoff
established for tuberculosis infection17, suggesting no interference
of MTBVAC at least in this target population. Interestingly, it
has been reported that individuals with a quantiFERON value
greater than 4 IUml 1 have a higher probability of developing
active TB, while individuals with a value between 0.35 and 4
(cutoff for positivity is 0.35) have a similar probability than
negative individuals41. Thus, this study opens the possibility
to reconsider the cutoff of this technique to identify individuals
with a high risk of developing active TB. Current clinical trials in
TB-endemic countries in neonates (NCT02729571) are further
evaluating quantiFERON conversion following MTBVAC
vaccination to evaluate this question in more detail.
MTBVAC is the only vaccine in the TB vaccine pipeline of
candidates in clinical evaluation that primes both CFP10- and
ESAT6-specific immune responses42. Our data suggest that this
strategy might be effective in protecting from pulmonary TB,
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Figure 5 | Enriched in vivo expression of genes from ESX-1 secretion
system. (a,b) Expression of esat6, cfp10, espA, espC, fbpA and fbpB genes
(normalized with 16s gene expression) from H37Rv isolated from lungs
from C3H/HeNRj (a) and C57BL/6 (b) 4 weeks after high-dose (103 CFU)
intranasal challenge, in comparison to expression obtained under
7H9-culture in vitro conditions. Normalized results are represented for each
gene and experimental condition as the fold-change induction in
comparison to fbpB expression level. In vivo data are derived from n¼4
mice (a) and n¼ 6 mice (b). In vitro data represent a pool of four
independent RNA extractions. All data are mean±s.e.m. *Po0.05;
**Po0.01; ***Po0.001; ****Po0.0001 by unpaired t-student test.
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which would have an evident impact on TB transmission.
Supporting this hypothesis, prospective cohort studies of persons
exposed to individuals with active TB have indicated that latently
infected individuals (reactive to CFP10 and ESAT6 stimulation)
are more protected against reinfection than non-infected
people43. Our data support the potential usefulness of the
analysis of CFP10- and ESAT6-positive cells after vaccination in
future clinical efficacy trials, in the search for a possible
biomarker of vaccine-induced protection.
Methods
Bacteria. M. bovis BCG Danish (Statens Serum Institute), M. tuberculosis
MTBVAC (University of Zaragoza) and M. tuberculosis H37Rv (Institut Pasteur
Paris) strains were grown at 37 C in Middlebrook 7H9 broth (Difco)
supplemented with ADC 10% (Difco) and 0.05% (v/v) Tween-80 (Sigma) or
on solid Middlebrook 7H11 (Difco) supplemented with ADC 10%. Bacterial
suspensions for vaccination or infection were prepared in PBS from glycerol stocks
previously quantified by plating serial dilutions.
Mouse experiments. All mice were kept under controlled conditions and
observed for any sign of disease. Experimental work was conducted in agreement
with European and national directives for protection of experimental animals
and with approval from the Ethics Committee from University of Zaragoza
(approved protocol PI46/14). No randomization specific methodology was
applied to this study.
Female, 8–10 weeks old C57BL/6, BALB/c and C3H/HeNRj mice
(Janvier Biolabs) were vaccinated subcutaneously (100 ml) with 106 CFU of vaccine
strains in PBS. Eight weeks post vaccination, mice were intranasally challenged
with 150 CFU of H37Rv in 40ml of PBS. Bacterial burden was assessed 4 weeks post
challenge by plating homogenized lungs and spleen on solid medium. A group of
infected mice was killed 1 day after challenge to determine the initial bacterial load
in lungs, which resulted to beB20 CFU in all experiments (Supplementary Fig. 6).
For immunogenicity studies, mice were vaccinated subcutaneously with 106
CFU of vaccine strains in PBS, and 8 weeks later animals were killed and
splenocytes collected. 106 cells were stimulated in 96-well U bottom plates with
PPD (Statens Serum Institute, SSI) 5 mgml 1, or 2 mgml 1 of ESAT6, CFP10 or
Ag85B (LIONEX GmbH, Braunschweig, Germany) during 48 h for supernatant
collection and cytokine detection by ELISA. Cytokine concentration in
supernatants was determined with an IFNg-specific ELISA kit (MabTECH). For
intracellular staining, splenocytes were incubated with antigens for 24 h, and
10 mgml 1 Brefeldin A (Sigma) was added during the last 6 h of incubation. For
surface staining, cells were labelled with anti-CD4-FITC (553047, BD Biosciences)
and anti-CD3-PerCPVio700 (130-109-883, Miltenyi Biotec), diluted 1:500 and
1:50, respectively, in culture medium with 10% FCS. Then, cells were fixed and
permeabilized with the Cytofix/Cytoperm Fixation/Permeabilization Kit
(BD Biosciences) following the manufacturer’s instructions, and stained with
anti-IFNg-APC (554413, BD Biosciences), diluted 1:200 in permeabilization buffer.
Cells were acquired with a Gallios Flow Cytometer (Beckman).
Construction of MTBVAC mutant substrains. We developed a BAC-rec strategy
to accelerate knockout construction in M. tuberculosis, which allowed to generate
the desired mutant strains in B1 month. To construct the allelic exchange
substrate (AES), we used a M. tuberculosis H37Rv bacterial artificial chromosome
(BAC) library constructed in the pBeloBAC11 vector and introduced into
Escherichia coli DH10B44 (a kind gift from Roland Brosch, Institut Pasteur Paris,
France). The E. coli clone carrying the BAC containing the target gene was
identified (Rv221 for fbpB and Rv414 for cfp10-esat6). Bacteria were made
electrocompetent and transformed with pKD46 carrying the red recombinase from
lambda phage45. The resulting E. coli strain was transformed with a PCR product,
which contains the kanamycin-resistant marker (Kmr) from pKD4 (ref. 45) flanked
by 40 bp homology arms to the target gene located in the BAC (using E6C10
P1/E6C10 P2 or Ag85B P1/Ag85B P2 primer pairs, Table 1). After induction of the
lambda red recombinase by incubation in the presence of 1mM L-arabinose,
recombinant colonies were selected by plating in the presence of kanamycin. Gene
disruption in the BAC was confirmed by PCR, resulting in a highly efficient process
with nearly 100% positive clones. The BAC carrying the disrupted allele(s) was
used as a template for a PCR reaction using the Pwo high fidelity DNA polymerase.
The final PCR product was subsequently used as AES and contains the Kmr
cassette with 1,500 bp homology arms flanking the target gene(s) (using E6C10
P1A/E6C10 P2A or Ag85B P1A/Ag85B P2A primer pairs, Table 1). In parallel,
MTBVAC transformed with pJV53H (a kind gift from Christophe Guilhot, IPBS,
Toulouse, France), which consists on the replacement of the original Kmr with a
hygromycin-resistance marker in pJV53 (ref. 46), was grown in the presence of
0.2% acetamide to allow expression of the recombinase system from this plasmid.
The AES was transformed in these cells by electroporation. Recombinant
MTBVAC colonies containing the desired mutation were selected by plating on
kanamycin and confirmed by PCR amplified with primers flanking the deleted
gene (using E6C10 Fw/E6C10 Rv or Ag85B Fw/Ag85B Rv primer pairs, Table 1).
Some of the colonies analysed contained both wild-type and mutant amplicons
suggesting an unspecific recombination of the AES. We selected colonies where
only the mutant amplicon was amplified (Supplementary Fig. 4 and Table 2).
50
40
30
20
10
0
SF
C 
(C
FP
10
)
0 210
MTBVAC
P = 0.043
a
Days post-vaccination
50
40
30
20
10
0
SF
C 
(C
FP
10
)
0 210
BCGb
Days post-vaccination
MTBVAC
50
40
30
20
10
0
SF
C 
(E
SA
T6
)
0 210
P= 0.1641
c
Days post-vaccination
50
40
30
20
10
0
SF
C 
(E
SA
T6
)
0 210
BCGd
Days post-vaccination
Figure 6 | Vaccination with MTBVAC induces a CFP10-specific immune response in humans. Specific IFNg ELISPOT results from the first-in-human
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In vitro presentation assay. Bone marrow cells collected from mouse femurs and
tibias were plated on sterile Petri dishes and incubated for 7 days in Dulbecco’s
modified Eagle’s medium (Gibco) containing 10% (v/v) heat-inactivated FCS,
100 units ml 1 penicillin/100mgml 1 streptomycin (Sigma) and 10% (vol/vol)
conditioned medium from mouse L929 fibroblasts (a kind gift from Dr Esther
Perez, GSK, Tres Cantos, Madrid, Spain). 105 bone-marrow-derived macrophages
were seeded in 96 flat-well plates and incubated for 4 h with CFP10 antigen at the
indicated concentrations in triplicates. After three washing steps with PBS, 106
purified CD4þ splenocytes obtained by MACS separation (Miltenyi Biotec)
(purity higher than 90 %) were added in 200 ml of RPMI 1640 (Sigma) containing
10% (v/v) heat-inactivated FBS, 100 unitsml 1 penicillin, 100mgml 1
streptomycin, 50mM 2-mercaptoethanol (Sigma) and cells were incubated for 24 h.
The plate was then centrifuged at 800g, and the supernatant recovered to determine
IFNg by ELISA (MabTECH).
Protein analysis. To analyse proteins from extracellular and intracellular
compartments, BCG, MTBVAC or H37Rv were cultured in 7H9 liquid medium
with 0.05% (v/v) Tween-80 and supplemented with 0.2% (w/v) dextrose and
0.085% (w/v) NaCl, to avoid albumin contamination from ADC in the supernatant
fraction. After 3 weeks of incubation, cultures were pelleted by centrifugation and
the supernatants were passed through 0.2 mm-pore filters to remove any residual
bacteria. Supernatant proteins were precipitated with 10% (v/v) trichloroacetic acid
(Sigma) during 1 h in ice and centrifugation at 3,200g during 30min at 4 C.
Pelleted proteins were rinsed with cold acetone and, after decanting acetone,
air dried pellets were resuspended in 150mM Tris/HCl pH 8. Bacterial pellet was
washed twice and resuspended in 1ml PBS containing a protease inhibitor cocktail
(Roche). Bacteria were disrupted by sonication for 30min at 4 C using a Bioruptor
(Diagenode). Samples were centrifuged 5min at 18 000g and the supernatant
collected for further analysis.
Intracellular and secreted protein concentrations were determined with the
QuantiPro BCA Assay kit (Sigma). Ten micrograms of protein per well were loaded
and separated by SDS–PAGE. Following protein transference to PVDF
membranes, immunodetection was carried out using mouse monoclonal antibodies
anti-ESAT6 (1:1,000; clone 11G4; Abcam ref.: ab26246) and anti-GROEL
(1:500; clone BDI578; Abcam ref.: ab20045), rabbit polyclonal anti-CFP10
(1:2,000; Thermo Scientific ref.: PA1-19445) and chicken polyclonal anti-Ag85A
(1:1,000; Abcam ref.: ab14073). Membranes were incubated with the corresponding
HRP-conjugated secondary antibodies (1:20,000; Sigma) and signal developed with
the ECL Plus Western Blotting System (GE HealthCare). To reprobe each blot with
different antibodies, membranes were incubated with ReBlot Plus Strong Antibody
Stripping Solution (Millipore) according to the manufacturer’s instructions.
For visualization of proteins following electrophoresis, polyacrylamide gels were
stained using a commercial colloidal blue staining kit (Invitrogen) according to the
manufacturer’s instructions. Bands of interest were split and sent for identification
by MALDI-TOF MS to Proteomics Services of the University of Zaragoza.
qRT–PCR. Groups of C3H/HeNRj or C57BL/6 8–10 weeks old, female mice were
intranasally challenged with 103 CFU of H37Rv in 40 ml of PBS. Four weeks later,
mice were killed individually and lungs collected and cut in small pieces, which
were homogenized in 4ml of TRIZOL by mechanical disruption using a Dounce
tissue grinder. Lung homogenates were split in four 1-ml aliquots and placed in dry
ice until further processing. Then, 200 ml of chloroform were added per ml of
TRIZOL and after vigorous vortexing, tubes were centrifuged at 18,000g during 1 h
at 4 C. Aqueous upper phase containing eukaryotic RNA was recovered and stored
at  80 C. Remaining supernatant was discarded and the four pellets containing
mycobacteria were resuspended and collected with one additional millilitre of
TRIZOL and 200 ml of chloroform. Bacteria were disrupted adding glass beads
using a Fast Prep device, with two 450 0 cycles at highest speed. Then, tubes were
centrifuged 10min at 18,000g (4 C) and aqueous phase (500 ml approx.) containing
mycobacterial RNA (and also remaining eukaryotic RNA) were recovered.
A measure of 700ml of isopropanol was added and tubes were incubated at room
temperature during 15min to favour RNA precipitation. Precipitated nucleic acids
were collected by centrifugation. The pellets were rinsed with 70% ethanol and air
dried before being re-dissolved in RNase-free water. DNA was removed from RNA
samples with TurboDNAfree (Ambion) by incubation at 37 C for 1 h. RNA
integrity was assessed by agarose gel electrophoresis, and absence of contaminating
DNA was checked by lack of amplification products after 30 PCR cycles. Lungs
from uninfected animals were processed as above to be used as non-infected
control in the qPCR.
For qRT–PCR, retro-transcription of 1 mg of RNA was performed following a
standard reverse transcription reaction with the SuperScript Reverse Transcriptase
(Invitrogen). The generated cDNA served as a template for qPCR in the presence of
gene-specific primers (Table 1) and SYBR Green Master-Mix (Roche). Four
Table 1 | Primer list.
Primer Primer sequence 50-30 Application
16S Fw ATGACGGCCTTCGGGTTGTAA qRT–PCR
16S Rv CGGCTGCTGGCACGTAGTTG qRT–PCR
ESAT6 Fw AGGGTGTCCAGCAAAAATGG qRT–PCR
ESAT6 Rv CTGCAGCGCGTTGTTCAG qRT–PCR
CFP10 Fw GCAGGAGGCAGGTAATTTCG qRT–PCR
CFP10 Rv CCTGGTCGATCTGGGTTTTC qRT–PCR
Ag85A Fw ATGCAGCTTGTTGACAGGGTT qRT–PCR
Ag85A Rv TCGACGCGACATACCCGT qRT–PCR
Ag85B Fw GGTTCAGTTCCAGAGCGGTG qRT–PCR
Ag85B Rv TCGAGCAGATAAACCGCAGG qRT–PCR
EspA Fw GGCACCCTCGGAGAAGTGT qRT–PCR
EspA Rv AGCTCTTTCAGGCCGTTGAG qRT–PCR
EspC Fw TGTACTTGACTGCCCACAATGC qRT–PCR
EspC Rv TCGACACCGGCCGTATG qRT–PCR
E6C10 P1 ACATTTTGGCGAGGAAGGTAAAGAGAGAAAGTAGTCCAGCGTGTAGGCTGGAGCTGCTTC MTBVACDE6C10
E6C10 P2 GATCCCGTGTTTCGCTATTCTACGCGAACTCGGCGTTGCCCATATGAATATCCTCCTTAGT MTBVACDE6C10
E6C10 Fw TCCCGTAATGACAACAGACTTC MTBVACDE6C10
E6C10 Rv GGAAGAGCTTGTCGTAGTCG MTBVACDE6C10
E6C10 P1A AGCGGATTTGACGTCGTGCT MTBVACDE6C10
E6C10 P1B CGATTGTCGCCCTACCCGAT MTBVACDE6C10
Ag85B P1 CCCGAGCACACGACGACATACAGGACAAAGGGGCACAAGTGTGTAGGCTGGAGCTGCTTC MTBVACDAg85B
Ag85B P2 ATCTCACGTGGACGGGTAAGCAACCCTTCGGTTGATCCCGCATATGAATATCCTCCTTAGT MTBVACDAg85B
Ag85B Fw ACATTTGGCCTCCACACAC MTBVACDAg85B
Ag85B Rv CAATCAGCGACAACAGGATGCC MTBVACDAg85B
Ag85B P1A TAGCACTCGAGTGATCGGCT MTBVACDAg85B
Ag85B P1B CCTCGAACCAACCGCCTTC MTBVACDAg85B
Table 2 | Plasmid and BAC information.
BAC or plasmids Source Reference
H37Rv BAC Library Institut Pasteur Paris (France) 44
pKD46 Coli Genetic Stock Center
(Yale University)
45
pKD4 Coli Genetic Stock Center
(Yale University)
45
pJV53H IPBS (Toulouse, France) 46
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replicates of each gene CT value were obtained in the StepOne Plus Instrument
(Applied Biosystems) and were normalized to the CT of the 16s rRNA gene
(amplified from the same samples), obtaining a DCT¼CT,j–CT,16S, where j is a gene
different from 16s. Our observations indicated unspecific gene amplification in the
non-infected cDNA controls. As a result, following a procedure previously
reported47, we calculated a DDCT value specific for infection (DDCT(inf)),
subtracting the DCT mean value for each gene obtained from non-infected controls
from the DCT obtained for each sample from infected mice. Finally, change was
calculated with the equation 2DDCTðinfÞ . Gene expression analysis from in vitro
samples was performed using conventional comparative CT method. Normalized
gene expression data (using the 16s rRNA as housekeeping gene) were represented
as the fold-change compared to fbpB expression for each of the in vivo and in vitro
conditions tested. The melting curves for all gene-specific primer pairs
(sequences used in Supplementary Experimental Procedures) were examined to
identify primer-dimer formation and to ensure the uniformity of the amplicons.
Statistical analysis. Results from this study were not blinded for analysis. No
statistical method was used to calculate sample size in animal experiments.
GraphPrism software was used for statistical analysis. Brown–Forsythe test was
used to assess variances homogeneity. Variances were similar among compared
groups. Statistical tests used for each experiment are indicated in the figure legends.
All statistical tests used were two-tailed. Outlier values were determined applying
the Grubb’s test to all data sets, and were discarded from the final statistical
analysis. Differences were considered significant at Po0.05.
Data availability. The authors declare that the data supporting the findings of this
study are available in this article and its Supplementary Information Files, or from
the corresponding authors on request.
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